Iskalni niz:
išči po
išči po
išči po
išči po
Vrsta gradiva:
Jezik:
Št. zadetkov: 2
Calcitonin and procalcitonin measurement after cholecystokinin-2/gastrin receptor agonist stimulation in patients with advanced medullary thyroid cancer
Malgorzata Trofimiuk‑Müldner, Katica Bajuk-Studen, Paola Erba, Luka Ležaič, Clemens Decristoforo, Katja Zaletel, Petra Kolenc-Peitl, Elwira Przybylik‑Mazurek, Irene Virgolini
Izvirni znanstveni članek
Oznake: medullary thyroid cancer;calcitonin;procalcitonin;cholecystokinin-2/gastrin receptor agonist;
Introduction: Medullary thyroid cancer (MTC) is characterized by overexpression of cholecystokinin-2/gastrin receptors (CCK2R). There are limitations of calcitonin as a tumor marker in MTC diagnosis and prognosis. Procalcitonin is gaining a role as a complementary tumor marker. This study aimed to a ...
Leto: 2025 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Development of the 99mTc-labelled SST2 antagonist TECANT-1 for a first-in-man multicentre clinical study
Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Krošelj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc-Peitl, Clemens Decristoforo, Piotr Garnuszek
Izvirni znanstveni članek
Oznake: tehnecij-99m;antagonisti receptorjev somatostatina;formulacija kompleta;toksičnost enkratnega odmerka;SPECT;radiofarmacevtiki;nevroendokrine neoplazme;technetium-99m;somatostatin receptor antagonists;kit formulation;single dose toxicity;radiopharmaceuticals;neuroendocrine neoplasms;
Broad availability and cost-effectiveness of 99Mo/99mTc generators worldwide support the use, and thus the development, of novel 99mTc-labelled radiopharmaceuticals. In recent years, preclinical and clinical developments for neuroendocrine neoplasms patient management focused on somatostatin recepto ...
Leto: 2023 Vir: Fakulteta za farmacijo (UL FFA)
Št. zadetkov: 2
Ključne besede:
Leto izdaje:
Avtorji:
Repozitorij:
Tipologija:
Jezik: